Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS
Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrough Therapy designation to tolebrutinib for treating non-relapsing secondary progressive multiple ...
Multiple Sclerosis News Today5d
Tolebrutinib for SPMS granted FDA breakthrough therapy designation
Tolebrutinib, expected to soon be submitted for U.S. approval for nonrelapsing SPMS, was granted the FDA's breakthrough ...
Daily5d
Sanofi gets USFDA Breakthrough Therapy designation for multiple sclerosis therapy Tolebrutinib
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Sanofi's Tolebrutinib Gets FDA Breakthrough Therapy Designation For NrSPMS
French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy ...
Sanofi: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with non-r ...
PMLiVE5d
Sanofi’s BTK inhibitor tolebrutinib granted FDA breakthrough designation for MS
Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor tolebrutinib has been granted breakthrough therapy ...
Zacks.com on MSN9d
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS
The FDA bestows a Breakthrough Therapy designation to Sanofi's tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis.
Daily9d
USFDA grants Breakthrough Therapy designation to Sanofi tolebrutinib for non-relapsing secondary progressive multiple sclerosis
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
The Pharma Letter9d
FDA status for Sanofi’s tolebrutinib in non-relapsing secondary progressive MS
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...